Nervous too. Even if it is approved for human testing, which seems like a no brainer, there's a chance it won't work quite the same. However, that's no reason for Invivo to throw the baby out with the bathwater. It may need some tweeking. If they don't hit a homerun right off the bat, eventually, they will figure it out. I'm not a day trader, so I'm not looking for an immediate payout, just promising companies. I think you have to look at the big picture here. Science moves slowly and there are a lot of bumps in the road.
I agree with your sentiment, fish, but I just can't imagine NVIV not being bought out before five years. Didn't FR allude to the fact that they have already had some nibbles, but, that he, holding about 40% of the shares, is not yet ready to sell? Either way, the payoff should be handsome. Right now, though, let's just obtain FDA approval for human trials, get the new manufacturing facility up and running, and announce a partnership for developing the hydrogel. Ultimately, the greatest appeal of this company is that it is a creating a new treatment PLATFORM. Platform, platform, platform...I love the potential of that word.
Word is that in order to start this trial InVivo needs to have its new manufacturing facilities running and a batch of its scaffold devices made in their new facility and approved and inspected by the FDA before it can begin this trial.